Evidence for lirilumab single-agent activity in lymphoma
Demonstration of enhanced efficacy of anti-CD20 antibodies when combined with lirilumab
To be presented at ASH meeting, December 9, abstract available online now
MARSEILLE, France, Nov. 14, 2013 (GLOBE NEWSWIRE) -- Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH), the innate immunity company developing first-in-class drug candidates for cancer and inflammatory diseases, announces that a new set of preclinical data on lirilumab will be presented in a poster at the upcoming 55th ASH Annual Meeting (December 7-10, 2013) in New Orleans, LA: "Anti-KIR Antibody Enhancement Of Anti-Lymphoma Activity Of Natural Killer Cells As Monotherapy and In Combination With Anti-CD20 Antibodies" Session Name: 625. Lymphoma: Pre-Clinical - Chemotherapy and Biologic Agents: Poster III Date: Monday, December 9, 2013 Presentation Time: 6:00 PM - 8:00 PM Location: Ernest N. Morial Convention Center, Hall G The abstract is available on the meeting website. Lirilumab is a natural killer (NK) cell checkpoint inhibitor undergoing clinical development with partner Bristol-Myers Squibb in Acute Myeloid Leukemia in monotherapy and in combination settings in solid tumors. The new preclinical results are from research conducted by Dr Holbrook Kohrt from Stanford University, Innate Pharma and CIML 1. They support the monotherapy activity of lirilumab in mouse models of lymphoma, through the enhancement of NK cell cytotoxicity. Furthermore, the new data showed that in combination with the anti-CD20 antibody rituximab*, lirilumab enhanced NK cell-mediated, antibody-dependent cellular cytotoxicity (ADCC) against lymphoma in vitro and in vivo in mouse models. Taken together, these data reinforce the rationale for the development of lirilumab in onco-hematology, and open new perspectives for the combination of lirilumab with antibody drugs active through ADCC. Nicolai Wagtmann, CSO of Innate Pharma, said: "What is particularly exciting and impressive about these new preclinical results is that we show that lirilumab, beyond single-agent activity, also enhanced the efficacy of rituximab in vivo through ADCC. These results raise the possibility that lirilumab may similarly enhance the ADCC-activity of other therapeutic antibodies currently marketed or in clinical development in cancer and other indications."About lirilumab (IPH2102/BMS-986015): Lirilumab is a fully human monoclonal antibody blocking interaction between Killer-cell immunoglobulin-like receptors (KIR) on NK cells with their ligands. Blocking these receptors facilitates activation of NK cells and, potentially, destruction of tumor cells by the latter.